Dupilumab: An emerging therapy in allergic fungal rhinosinusitis

Adeeb A Bulkhi; Ahmad A Mirza; Abdullah J Aburiziza; Osama A Marglani

doi:10.1016/j.waojou.2022.100638

Dupilumab: An emerging therapy in allergic fungal rhinosinusitis

World Allergy Organ J. 2022 Mar 30;15(3):100638. doi: 10.1016/j.waojou.2022.100638. eCollection 2022 Mar.

Authors

Adeeb A Bulkhi^{1

2

3}, Ahmad A Mirza^{4

5}, Abdullah J Aburiziza⁶, Osama A Marglani^{7

8}

Affiliations

¹ Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
² Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, Fl, USA.
³ Department of Allergy and Immunology, King Abdullah Medical City, Makkah, Saudi Arabia.
⁴ Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia.
⁵ Department of Otolaryngology-Head and Neck Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
⁶ Department of Pediatrics, Umm Al-Qura University (UQU), Makkah, Saudi Arabia.
⁷ Department of Ophthalmology, and Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
⁸ Department of Surgery, King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.

Abstract

Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). This case series reports 4 patients with resistant AFRS concomitant with asthma, for which dupilumab therapy was administered. Long-term follow-ups showed that dupilumab improved the symptoms and improved the results of objective tools such as imaging and pulmonary function test.

Keywords: Biological therapies; Hypersensitivity; Nasal polyp; Saudi Arabia; Sinusitis.